International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(8), С. 4323 - 4323
Опубликована: Апрель 13, 2024
Neurodegenerative
disorders
(NDs)
represent
a
group
of
different
diseases
characterized
by
the
progressive
degeneration
and
death
nervous
system's
cells.
The
diagnosis
is
challenging,
especially
in
early
stages,
due
to
no
specific
clinical
signs
symptoms.
In
this
context,
laboratory
medicine
could
support
clinicians
detecting
differentiating
NDs.
Indeed,
biomarkers
indicate
pathological
mechanisms
underpinning
ideal
biofluid
for
NDs
cerebrospinal
fluid
(CSF),
which
has
limitations,
hampering
its
widespread
use
practice.
However,
intensive
efforts
are
underway
introduce
high-sensitivity
analytical
methods
detect
ND
alternative
nonivasive
biofluid,
such
as
blood
or
saliva.
This
study
presents
an
overview
molecular
currently
used
For
some
diseases,
Alzheimer's
disease
multiple
sclerosis,
well
established
recommended
guidelines.
most
NDs,
research
ongoing
identify
reliable
biomarkers,
consensus
yet
been
achieved.
Psychiatry Research,
Год журнала:
2024,
Номер
333, С. 115760 - 115760
Опубликована: Янв. 28, 2024
The
nature
of
the
relationship
between
sleep
problems
and
dementia
remains
unclear.
This
study
investigated
measures
in
older
adults
(≥
65)
using
data
from
English
Longitudinal
Study
Ageing
(ELSA)
further
causal
association
Mendelian
randomization
(MR)
analysis.
In
total
7,223
individuals,
5.7
%
developed
(1.7
Alzheimer's
disease
(AD))
within
an
average
8
(±
2.9)
years.
Cox
regression
models
MR
were
employed.
Long
duration
(>8
h)
was
associated
with
64
increased
risk
incident
2-fold
high
AD
compared
to
ideal
(7-8
h).
particularly
evident
older-older
(≥70
years)
those
who
consumed
alcohol.
Short
(<7
lower
among
but
higher
younger-older
adults.
Sleep
disturbances
perceived
quality
not
or
AD.
did
reveal
associations
dementia.
These
findings
suggest
that
self-reported
short
long
frequent
alcohol
consumption
are
Early
detection
these
patterns
may
help
identify
individuals
at
risk.
Journal of Alzheimer s Disease Reports,
Год журнала:
2024,
Номер
8(1), С. 203 - 240
Опубликована: Фев. 16, 2024
Background:
Alzheimer’s
disease
(AD)
causes
progressive
decline
of
cognition
and
function.
There
is
a
lack
systematic
literature
reviews
on
prognostic
predictive
factors
in
its
early
clinical
stages
(eAD),
i.e.,
mild
cognitive
impairment
due
to
AD
dementia.
Objective:
To
identify
affecting
eAD
progression
for
treatment
efficacy
safety
approved
and/or
under
late-stage
development
disease-modifying
treatments.
Methods:
Databases
were
searched
(August
2022)
studies
reporting
associated
with
response.
The
Quality
Prognostic
Factor
Studies
tool
or
the
Cochrane
risk
bias
used
assess
bias.
Two
reviewers
independently
screened
records.
A
single
reviewer
performed
data
extraction
quality
assessment.
second
20%
check.
Content
experts
reviewed
interpreted
collected.
Results:
Sixty-one
included.
Self-reporting,
diagnosis
definition,
missing
led
high
Population
size
ranged
from
110
11,451.
Analyses
found
indicating
that
older
age
was
depression
may
be
progression.
Greater
baseline
APOE4
factor,
factor
predicts
an
adverse
response
(ARIA).
Elevated
biomarkers
(CSF/plasma
p-tau,
CSF
t-tau,
plasma
neurofilament
light)
Conclusions:
Age
strongest
Biomarkers
progression,
supporting
their
use
trial
selection
aiding
diagnosis.
Baseline
factor.
predicted
ARIA,
aligning
emerging
evidence
relevant
initiation/monitoring.
RSC Advances,
Год журнала:
2024,
Номер
14(15), С. 10304 - 10321
Опубликована: Янв. 1, 2024
Monoamine
oxidases
(MAOs)
inhibitors
could
decrease
reactive
oxygen
species
(ROS)
generation,
enhance
mono-aminergic
neural
transmission,
and
have
major
therapeutic
benefits
for
the
treatment
of
Alzheimer's
disease
(AD).
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(8), С. 4323 - 4323
Опубликована: Апрель 13, 2024
Neurodegenerative
disorders
(NDs)
represent
a
group
of
different
diseases
characterized
by
the
progressive
degeneration
and
death
nervous
system's
cells.
The
diagnosis
is
challenging,
especially
in
early
stages,
due
to
no
specific
clinical
signs
symptoms.
In
this
context,
laboratory
medicine
could
support
clinicians
detecting
differentiating
NDs.
Indeed,
biomarkers
indicate
pathological
mechanisms
underpinning
ideal
biofluid
for
NDs
cerebrospinal
fluid
(CSF),
which
has
limitations,
hampering
its
widespread
use
practice.
However,
intensive
efforts
are
underway
introduce
high-sensitivity
analytical
methods
detect
ND
alternative
nonivasive
biofluid,
such
as
blood
or
saliva.
This
study
presents
an
overview
molecular
currently
used
For
some
diseases,
Alzheimer's
disease
multiple
sclerosis,
well
established
recommended
guidelines.
most
NDs,
research
ongoing
identify
reliable
biomarkers,
consensus
yet
been
achieved.
